Diazoxide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Diazoxide
- Diazoxide: From Antihypertensive/Hyperinsulinism Therapy to Hypotrichosis Simplex of the Scalp
Diazoxide: From Antihypertensive/Hyperinsulinism Therapy to Hypotrichosis Simplex of the Scalp
One-Sentence Summary
Diazoxide is a KATP-channel opener historically used as an antihypertensive agent and, more recently, as the first-line treatment for hyperinsulinaemic hypoglycaemia (congenital hyperinsulinism). The TxGNN model predicts it may be effective for Hypotrichosis Simplex of the Scalp, a rare genetic hair-loss disorder, but this specific prediction currently has no supporting clinical trials or literature in the evidence pack — it is a similarity-based model signal only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not confirmed via UK regulatory data (diazoxide is not currently marketed in the UK); literature within this evidence pack describes historical use as an antihypertensive agent and as first-line therapy for hyperinsulinaemic hypoglycaemia (congenital hyperinsulinism) |
| Predicted New Indication | Hypotrichosis Simplex of the Scalp |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for diazoxide is not available in this evidence pack. Based on the literature captured under related predictions, diazoxide is known to act as a KATP-channel opener/agonist (acting on SUR1/Kir6.2 in pancreatic β-cells), and systemic use is well documented to cause hypertrichosis (excess hair growth) as a recognised side effect — a pharmacological property it shares with minoxidil, an established hair-growth treatment with the same channel-opening mechanism.
However, for this specific predicted indication — hypotrichosis simplex of the scalp, a rare monogenic form of hair thinning distinct from androgenetic alopecia — the evidence pack explicitly states there is no direct literature, trial, or mechanistic support. The prediction rests purely on TxGNN embedding similarity to semantically neighbouring terms such as alopecia and hypertrichosis, rather than on any demonstrated drug–disease relationship.
It is worth noting that a related, lower-ranked prediction in the same evidence pack — general “alopecia” — does have preclinical and case-level support (topical diazoxide stimulating hair regrowth in primate models, and hypertrichosis as a class effect shared with minoxidil), reaching evidence level L3. This lends some indirect biological plausibility to diazoxide’s general hair-growth activity, but does not extend directly to the specific rare genetic disorder captured as the top-ranked prediction here.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
UK Market Information
Diazoxide is not currently marketed in the UK. No MHRA marketing authorisations are on record in this evidence pack (0 licences).
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (hypotrichosis simplex of the scalp) has no clinical trial or literature evidence and is supported only by a model similarity score (L5), and diazoxide currently has no UK marketing authorisation. There is insufficient basis to progress this specific indication.
To proceed, the following is needed:
- Direct clinical or literature evidence specific to hypotrichosis simplex of the scalp (none currently exists)
- Confirmed mechanism-of-action data for diazoxide (data gap in this pack)
- SmPC-level warnings and contraindications for a formal safety assessment (data gap in this pack; currently blocking)
- Clarification of a UK regulatory pathway, since the drug is not presently marketed here
- Consideration of the better-evidenced related candidate identified in the same evidence pack — “alopecia” (rank 4, evidence level L3, decision stage “Research Question”) — which has preclinical support and a clearer mechanistic rationale, and may warrant separate evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.